SCHEMBL6807680

SCHEMBL6807680

Cc1cccc(NC(=O)NCCc2ccccc2)c1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.64
ITGB3 P05106 2/20 0.55
ITGAV P06756 2/20 0.55
TRPV1 Q8NER1 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
ALOX12 P18054 1/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 3/20 0.52
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
EPHX1 P07099 2/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 2/20 0.50
CNR1 P21554 1/20 0.50
ITGB1 P05556 1/20 0.50
ITGA5 P08648 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496672 0.90 KMT2A (0.52) KMT2AITGB3ITGAVTRPV1SMN1; SMN2
SCHEMBL6498315 0.90 KMT2A (0.52) KMT2AITGB3ITGAVTRPV1SMN1; SMN2
SCHEMBL6497834 0.90 KMT2A (0.52) KMT2AITGB3ITGAVTRPV1SMN1; SMN2
SCHEMBL6498395 0.86 CNR1 (0.54) KMT2ASMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL6497268 0.81 ITGB3 (0.53) KMT2AITGB3ITGAVKDM4EMEN1
SCHEMBL27358385 0.79 CFD (0.72) KMT2ATRPV1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10362773 0.78 KMT2A (0.53) KMT2ATRPV1SMN1; SMN2ALDH1A1HPGD
SCHEMBL21045504 0.78 KMT2A (1.00) KMT2AITGB3ITGAVSMN1; SMN2ALDH1A1
SCHEMBL6500776 0.77 DDX3X (0.64) KMT2ASMN1; SMN2LMNAKDM4EMEN1
SCHEMBL6500550 0.75 KMT2A (0.56) KMT2ATRPV1ALDH1A1LMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683077-B2 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS G.D. SEARLE & CO. 2004-01-27 US disclosed
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. 2003-01-30 US disclosed
US-6380189-B1 FOR TREATING HERPES-RELATED DISORDERS G.D. SEARLE & CO. 2002-04-30 US disclosed
EP-0828721-B1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS SEARLE & CO (US) 2001-11-14 EP disclosed
CN-1070480-C 2-amino-benzoxanones for the treatment of viral infections SEARLE & CO (US) 2001-09-05 CN disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
EP-0828721-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1998-03-18 EP disclosed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, HAX1 KMT2A 1555/4885ITGB3 4766/4885ITGAV 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.